

**CURRICULUM VITAE  
MICHAEL W. CANNON, M.D.**

**Office Address:** Cancer Center of Kansas, P.A.  
818 N. Emporia, Suite 403  
Wichita, KS 67214

**Date of Hire:** 04/01/86

**Present Position:** Vice President, Cancer Center of Kansas, P.A.

**EDUCATION:**

<b>Undergraduate</b>	Wichita State University, Wichita, KS B.S. Chemistry	1972
	University of Kansas School of Medicine, Kansas City, KS M.D.	1975
<b>Postgraduate</b>	University of Kansas School of Medicine, Kansas City, KS Residency in Pathology	1975-77
	University of Kansas School of Medicine, Wichita, KS Residency in Internal Medicine	1977-80
	M. D. Anderson Hospital and Tumor Institute, Houston, TX Fellow, Medical Oncology	1980
	University of Kansas School of Medicine, Kansas City, KS Fellow, Medical Oncology	1981-82

**MEDICAL LICENSURE:** State of Kansas

**PROFESSIONAL CERTIFICATION:**

American Board of Internal Medicine	
Internal Medicine	11/94
Medical Oncology	1/96

**ACADEMIC APPOINTMENTS:**

University of Kansas School of Medicine - Wichita, Wichita, KS	
Clinical Assistant Professor of Medicine	1989-2000
Assistant Professor of Medicine	1992-

**HOSPITAL APPOINTMENTS:**

Veteran's Administration Medical Center - Wichita Staff Oncologist	1983-98
Via Christi Regional Medical Center, Wichita, KS St. Joseph campus: Secretary, Department of Internal Medicine Institutional Review Board	1988

**PROFESSIONAL SOCIETIES:**

American Medical Society  
Kansas Medical Society  
Southwest Oncology Group  
Sedgwick County Medical Society  
American Society of Clinical Oncology  
American College of Physicians  
Fellowship 1999  
American Board of Internal Medicine

**HONORS and AWARDS:**

Platinum Award ( $\geq 25$  patients Total Accruals in WCCOP NCI Treatment and Cancer Control Clinical Trials 2011  
Best in Oncology Medicine in Cowley County 2018, 2019  
Physician Health Care Hero by Wichita Business Journal 2018

**BIBLIOGRAPHY**

**Scientific papers submitted but not yet accepted:**

1. McKean H, Stella PJ, Hillman SL, Rowland KM, Cannon MW, Behrens RJ, Steen PD, Flynn PJ, Nair S, Jatoi A: Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: Results and conclusions from North Central Cancer Treatment Group study N0222. (February 2010)

**Scientific papers with single or multiple authors:**

1. Hensleigh PA, Glover DB, Cannon MW: Systemic Herpes Virus Homnis in Pregnancy. *J Reprod Med.* 1979;22:171-176.
2. Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR: Weekly Carboplatin and Paclitaxel in Elderly Non-Small Cell Lung Cancer Patients ( $\geq 65$  Years of Age): A Phase II North Central Cancer Treatment Group Study. *American Journal of Clinical Oncology.* 2003 Oct;26(5): 441-447.
3. Jatoi, A, Hillman S, Stella PJ, Mailliard JA, Sloan J, Vanone S, Cannon MW, Kutteh L, Kanard A, Jett JR: Daily Activities: Exploring Their Spectrum and Prognostic Impact in Older, Chemotherapy-Treated Lung Cancer Patients. *Support Care Cancer.* 2003; 11(7): 460-464.
4. Burch PA, Mailliare JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN: Phase II study of gemcitabine plus cisplatin in patients with metatstatic breast cancer. *American Journal of Clinical Oncology.* 2005 Apr;28(2):195-200.

5. McKean H, Stella PJ, Hillman SL, Rowland KM, Cannon MW, Behrens RJ, Gross GG, Sborov MD, Friedman EL, Jatoi A: Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222. *Cancer Invest.* 2011 May;29(4):266-271. Epub 2011 Feb 23.
6. Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM, Witzig TE: Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. *Blood.* 2011 Oct 13;118(15):4053-4061. Epub 2011 Jun 14.

**Abstracts:**

1. Cannon MW, Welch LK: Review of metastatic brain disease. Presented at American College of Physicians Regional Meeting, Kansas City, Missouri, 1980.
2. Skibba RM, Cannon MW: Campylobacter Enteritis. Presented at American College of Physicians Regional Meeting, Kansas City, Missouri, 1980.
3. Hynes HE, Dakhil SR, Rosen D, Zatzkin JB, Cannon MW, Moore DF, Crowley J: The Community Clinical Oncology Program (CCOP): The Wichita Model. *Proc Am Soc Clin Oncol* 1988;7:78 (#301).
4. Holoye PY, Winn RJ, Craig K, Goodwin W, Wade J, Cannon MW. Phase II study of Teniposide in small cell bronchogenic carcinoma. 1989;8:243 (#946). Presented at the University of Texas M. D. Anderson Cancer Center, Houston, TX.
5. Moore DF Jr, Moore DF Sr, Johnson DB, Cannon MW, Whisman SA, Church PS, Palko W, Dakhil SR, Hynes HE: Bethesda unit titer as a prognostic factor in patients with acquired factor 8 inhibitors. *Blood.* 84 (Suppl 1):680a (abstr #2705), 1994.
6. Dakhil SR, Hynes HE, Cannon MW, Johnson DB, Moore DF Jr: G-CSF plus Ciprofloxacin in the prevention of sepsis in patients with severe neutropenia related to chemotherapy. *Blood.* 84 (Suppl 1):24a (abstr #83), 1994.
7. Moore DF Jr, Moore DF Sr, Johnson DB, Bluml P, Cannon MW, Dakhil SR, Palko W, Hynes HE: Interleukin-2 (IL-2) therapy following autologous blood and marrow transplantation in Burkitt's lymphoma: Effect on lymphocyte subsets. *Proc Second Pan-Pacific Lymphoma Conference* 1995 (abstr).
8. Burch PA, Mailliard JA, Hillman DW, Perez EA, Drook JE, Rowland KM, Kugler JW, Cannon MW, Ingle JN: Phase II Study of Gemcitabine Plus Cisplatin in Patients with Metastatic Breast Cancer and Prior Chemotherapy Exposure: A North Central Cancer Treatment Group Trial.
9. Millikan R, Thall P, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade III J, Logothetis CJ: Randomized Multicenter Phase II Trial of Two Multicomponent Regimens in Androgen Independent Prostate Cancer. National Cancer Institute CA45809.
10. Mailliard JA, Jatoi A, Hillman S, Stella PJ, Vanone SG, Perez EA, Cannon MW, Geyer SM, Wiesenfeld M, Jett JR: Weekly carboplatin and paclitaxel in elderly non-small cell lung cancer patients (greater than or equal to 65 years of age): a phase II NCCTG study. *Proc Am Soc Clin Oncol* 21:383a, 2002.
11. Micallef IN, Maurer MJ, Nikcevich D, Cannon M, Moore D, Kurtin P, Witzig TE: A phase II study of

epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. *Proc Am Soc Clin Onc* 2008; 26(May 20s) abstr #8500.

12. Micallef IN, Maurer M, Nikcevich DA, Cannon MW, Schaefer E, Moore DF, Kurtin, PJ, Witzig TE: Final results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. *J Clin Oncol*. 2009; 27(15s): abstr #8508.
13. Wang J, Shi-Ming T, Pagliaro LC, Weiss M, Hajdenberg J, Tseng J, Wade JL, Bell RJ, Cannon MW, Fisch M: A prospective randomized phase III trial comparing consolidation therapy with or without strontium-89 following induction chemotherapy in androgen-independent prostate cancer. *J Clin Oncol*. 32, February 2014 (suppl 4; abstr 90)
14. Reddy PS, Rahal AK, Kallail KJ, Moore DF, Truong PV, Mattar BI, Cannon MW, Nabbout NH, Page SJ, Truong QV, Dakhil C, Deutsch JM, Dakhil SR: "The Application of Next-Generation Sequencing in the Community Clinical Oncology Setting." *J Clin Oncol*. 34, 2016 (suppl; abstr e23145)
15. Cmelak, Anthony J., et al. "Phase II Trial of Chemoradiation for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern Cooperative Oncology Group Study E2399." *The Journal of Clinical Oncology*. vol. 25, no. 25, September 2007, pp. 3971-3977., doi:10.1200/JCO.2007.10.8951.s

### **Poster Presentations:**

1. Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore Jr. DF, Kurtin P, Witzig TE: A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. *Proc Am Soc Clin Oncol* 2008;26. Clinical Science Symposium #8500.
2. Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore Jr. DF, Kurtin P, Witzig TE: A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. *International Lymphoma Conference* June 4-7, 2008, Palazzo Dei Congressi, Lugano, Switzerland.
3. Young, Derek, et al. "A Retrospective Analysis Comparing Efficacy of Filgastrim-sndz Versus Filgastrim for Autologous, Peripheral Stem Cell Mobilization in Patients With Multiple Myeloma and Lymphoma." Abstract #225533, submitted at *ASCO Annual Mtg*. 1-5 May 2018